Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2025 Aug 1:2025.08.01.25332579. [Version 1] doi: 10.1101/2025.08.01.25332579

Cognitive trajectories and incident atrial fibrillation in the ASPREE cohort

Amy Brodtmann, Nicholas Cheng, Emilio Werden, Johannes Neumann, Catherine Robb, Sharyn M Fitzgerald, Rory Wolfe, Andrew M Tonkin, Suzanne G Orchard, Joanne Ryan, Robyn L Woods, Caroline Gao, John J McNeil
PMCID: PMC12324613  PMID: 40766137

Abstract

Background

Atrial fibrillation (AF) is associated with aging and increased risk of stroke and dementia. We examined the association between incident AF and cognitive trajectories in older adults using longitudinal data from the ASPirin in Reducing Events in the Elderly (ASPREE) study.

Methods

ASPREE was a multi-center randomized, double-blind, placebo-controlled trial of low-dose (100 mg) aspirin in healthy older adults. In this analysis, participants were aged ≥70 years with no history of cardiovascular disease, AF, or a diagnosis of dementia. We used a case ascertainment approach to identify participants with new onset of probable AF over trial participation, defined by new anticoagulant use, incident medically documented diagnosis, or irregular heart rate at study visits prompting diagnosis. We generated z -scores for cognitive assessments for global cognition (3MS, Modified Mini-Mental State Examination), verbal fluency/executive function (Controlled Oral Word Association Test, COWAT-F), delayed memory (Hopkins Verbal Learning Test–Revised, HVLT–R), and attention/processing speed (Symbol Digit Modalities Test, SDMT). Baseline cognition and trajectories were compared between probable AF and no AF (control group) using linear mixed-effects models.

Results

Of 14,577 participants (mean age = 75.2 ± 4.3 years; 57.8% female), 978 (6.7%) developed probable AF. Baseline cognitive scores did not differ between groups. Compared to controls, those with AF showed greater decline over five years: 0.12 z -score (95% CI: 0.05, 0.20) in 3MS, 0.10 (95% CI: 0.07, 0.12) in COWAT, 0.10 (95% CI: 0.10, 0.16) in SDMT, and 0.11 (95% CI: 0.08, 0.14) in HVLT. APOE ℰ4 allele carriage was associated with greater decline among those with AF.

Conclusions

In initially healthy older adults, those who developed AF had comparable cognitive profiles at baseline but exhibited greater cognitive decline over 5 years than those who did not. A diagnosis of AF may be a trigger for cognitive evaluation in older individuals.

Clinical Trial Registration

www.clinicaltrials.gov/study/NCT01038583

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES